-
Lactate as a Metabolic–Immune Control Point
2026-09-12
Lactate is moving from a passive glycolytic readout to a mechanistic control point in tumor–immune biology. This article translates the NAT1–ENO1–lactate–TRAF6–PD-L1 axis into practical experimental guidance for metabolic flux, hypoxia, mitochondrial, and immunotherapy research.
-
Hepatic sEH, Nrf2, and Osteoclastogenesis in Osteoporosis
2026-09-11
A recent Free Radical Biology and Medicine study identifies hepatic soluble epoxide hydrolase as an upstream regulator of osteoclastogenesis through circulating 14,15-EET, inflammatory cytokines, and Nrf2–ARE signaling. Its liver–bone axis model provides a mechanistic framework for studying redox imbalance in osteoporosis and for designing target-engagement experiments around epoxide lipid metabolism.
-
PDHA1 Succinylation and Immune Escape in Cholangiocarcinoma
2026-09-11
The reference study identifies PDHA1 lysine 83 succinylation as a metabolic-immune switch in cholangiocarcinoma. By increasing PDH activity and promoting alpha-ketoglutaric acid accumulation, this modification activates macrophage OXGR1–MAPK signaling, suppresses MHC-II antigen presentation, and contributes to chemotherapy resistance.
-
HyperScript III RT SuperMix for CRC Validation
2026-09-10
HyperScript III RT SuperMix can strengthen qPCR validation of colorectal cancer biomarkers by combining genomic DNA contamination removal with high-yield cDNA synthesis. This article translates bile acid metabolism subtyping into practical assay-design and interpretation decisions.
-
Entecavir (BMS200475) for HBV Research Workflows
2026-09-10
Entecavir (BMS200475) provides a nanomolar benchmark for concentration-response, genotype-aware, and chronic hepatitis B virus replication inhibition assays. This workflow guide shows how to handle BA1816, compare wild-type and lamivudine-resistant HBV models, and interpret resistance findings without confusing in vitro potency with clinical outcomes.
-
FLAG tag Peptide: Assay Design for Exosomes
2026-09-09
The FLAG tag Peptide and DYKDDDDK peptide enable controlled recombinant protein detection and affinity purification. This article develops a practical assay framework for applying competitive FLAG elution to mechanistic exosome studies while distinguishing established evidence from workflow recommendations.
-
BIBP 3226 Trifluoroacetate: NPY/NPFF Probe
2026-09-09
BIBP 3226 trifluoroacetate is a non-peptide antagonist for NPY Y1 and NPFF receptor studies. Its binding, cAMP, storage, and solubility data support controlled NPY/NPFF system research, while cardiovascular applications remain mechanistic rather than clinical.
-
Probenecid: From Mechanism to Translation
2026-09-08
A mechanism-first framework for using Probenecid to study transporter-mediated multidrug resistance, pannexin-1 biology, and neuroprotection while separating established evidence from translational hypotheses.
-
Improving In Vitro Metrics for Cancer Drug Responses
2026-09-08
Hannah R. Schwartz’s dissertation addresses a persistent problem in cancer pharmacology: relative viability and fractional viability are often treated as interchangeable even though they capture different aspects of drug response. By separating growth inhibition from cell killing and considering their timing, the work offers a more informative framework for interpreting in vitro drug-response experiments and designing follow-up studies.
-
MLKL Polymerization, LMP, and Necroptosis
2026-09-07
The reference study identifies lysosomal membrane permeabilization as a major execution step downstream of MLKL polymerization during necroptosis. Its experiments connect MLKL recruitment to lysosomes with cathepsin B release and show that genetic or chemical suppression of cathepsin B can protect cells from necroptotic death.
-
LMTK2, Nrf2, and Microglial Inflammation
2026-09-05
Rui et al. examined how LMTK2 influences inflammation in LPS-stimulated BV2 microglia and identified a connection with the Nrf2/HO-1/NQO1 antioxidant pathway. LMTK2 overexpression reduced several inflammatory readouts, although the model and overexpression design require further validation before the findings can be extended to primary microglia or neuroinflammatory disease.
-
Aβ42 Peptide: Designing Causal AD Assays
2026-09-05
Amyloid β-Peptide (1-42) is more than an Alzheimer’s disease challenge reagent: it can anchor causal studies of neuronal toxicity, ion-channel disruption, and ferroptosis. This guide connects Aβ42 assay design with evidence from a Keap1–Nrf2 study to improve mechanistic interpretation and reproducibility.
-
Small-Molecule Optimization of hiPSC Platelets
2026-09-04
This 2026 study presents an optimized differentiation scheme for producing functional platelets from human induced pluripotent stem cells by combining higher embryoid body input, human platelet lysate, and small-molecule control of differentiation and megakaryocyte maturation. The approach shortened production to 19 days, achieved 14.9 platelets per iPSC, and reduced reported costs by 58.3%, providing a practical framework for scalable ex vivo platelet manufacturing.
-
O-GlcNAcylation Rewires Wnt-Driven Bone Formation
2026-09-04
The reference study identifies O-GlcNAcylation as a metabolic effector of Wnt3a-driven osteogenesis rather than a passive response to increased glucose flux. Its central mechanism links Wnt-dependent Ca2+-PKA-GFAT1 signaling and PDK1 stabilization to aerobic glycolysis, bone formation, and fracture healing, providing a framework for designing mechanistically resolved Wnt studies.
-
Ibotenic Acid: NMDA Receptor Agonist Guide
2026-09-03
Ibotenic acid is an NMDA receptor agonist and metabotropic glutamate receptor agonist used as a neuroscience research tool. Product specifications support controlled aqueous or DMSO preparation, while recent murine evidence shows dose- and time-dependent neurotoxicity that limits direct translation to human disease.